If GlucoChip remained as PSID asset, all related market infiltration accounting charges would hurt the company's balance (thus detracting from MBand & FireFly financing/grant/contract opportunities).
PSID management, by transferring product ownership in exchange for common stock and interest bearing warrants, have instead turned GlucoChip into a value certain balance sheet asset.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.